Cervical Cancer Screening & HIV: Suriname Study | Cureus

Cervical Cancer Screening & HIV: Suriname Study | Cureus

March 14, 2026 Nkechi Okonkwo- Health Editor Health

Cervical cancer screening is a critical component of preventative healthcare for all women, but it takes on added urgency for those living with HIV. Recent research and existing public health understanding, highlights the increased vulnerability of women with HIV to cervical cancer and the importance of tailored screening approaches. A study published in Cureus focuses specifically on this demand within Suriname, a country where both HIV prevalence and cervical cancer rates present significant public health challenges.

Understanding the Elevated Risk

Women living with HIV experience a higher incidence of cervical cancer and a more rapid progression from pre-cancerous lesions to invasive cancer. This is largely due to the immunosuppression caused by HIV, which weakens the immune system’s ability to fight off the Human Papillomavirus (HPV) – the primary cause of most cervical cancers. The Stichting Lobi Suriname explains that the development of cervical cancer can occur more quickly in women with HIV, potentially bypassing the typical 10-20 year progression seen in those without HIV. HPV is transmitted through sexual contact, and long-term infection with high-risk HPV types can lead to cellular changes in the cervix that, if left undetected and untreated, can develop into cancer.

The Suriname Context: A Retrospective Study

The Cureus study investigated cervical cancer screening practices in women living with HIV in Suriname. Although details of the study methodology are limited in the provided source, the research underscores the need for focused attention on this population. A related study, published in the Rev Panam Salud Publica in 2024, examined HIV prevalence among women diagnosed with (pre)cancerous cervical lesions in Suriname. This research, led by Deborah Stijnberg of Anton de Kom University of Suriname, highlights the intersection of these two health concerns within the country. The study aimed to determine the prevalence of HIV in women with cervical intraepithelial neoplasia (CIN I to CIN III) and their retention in care. The authors, including Regillio Charles from the Academic Hospital Paramaribo, Mike Mc Kee from the National AIDS Program, and others, sought to understand the challenges and opportunities for integrated HIV and cervical cancer prevention and treatment.

Screening Methods and Early Detection

Early detection is paramount in preventing cervical cancer. Screening methods, such as the Pap smear and the VIA (Visual Inspection with Acetic Acid) method, can identify pre-cancerous changes in the cervix, allowing for timely treatment and a 100% cure rate in many cases. The Stichting Lobi Suriname emphasizes that during the pre-cancerous stage, Notice often no noticeable symptoms, making regular screening even more crucial. Women may not realize they are at risk and may delay seeking medical attention until symptoms appear, at which point treatment may be more challenging.

The Role of HIV Status in Screening Frequency

Current guidelines, generally aligned with World Health Organization (WHO) recommendations, suggest that women living with HIV should undergo more frequent cervical cancer screening than HIV-negative women. This is because of the increased risk of rapid disease progression. While specific screening intervals vary depending on local resources and individual risk factors, annual screening is often recommended for women with HIV. It’s important to note that these are general recommendations, and individual screening plans should be determined in consultation with a healthcare provider.

Challenges and Considerations in Suriname

Suriname, like many countries, faces challenges in implementing comprehensive cervical cancer screening programs. These challenges can include limited access to healthcare services, particularly in rural areas, a lack of awareness about cervical cancer and HPV, and stigma associated with both HIV and sexual health. The retrospective nature of the Cureus study and the related research in Rev Panam Salud Publica suggests a need for ongoing monitoring and evaluation of screening programs to identify gaps in coverage and improve outcomes. Understanding retention in care – how consistently women attend follow-up appointments and receive necessary treatment – is also critical.

Beyond Screening: HPV Vaccination

While screening is essential for detecting and treating pre-cancerous lesions, prevention is equally important. HPV vaccination is a highly effective way to prevent infection with the most common cancer-causing HPV types. The WHO recommends that girls aged 9-14 years be vaccinated against HPV, but vaccination programs are not yet universally available or fully implemented in all countries, including Suriname. Expanding access to HPV vaccination is a key strategy for reducing the burden of cervical cancer, particularly among women living with HIV.

What Comes Next: Strengthening Integrated Care

Addressing the increased risk of cervical cancer in women living with HIV requires a multi-faceted approach that integrates HIV care and cervical cancer prevention services. This includes:

  • Routine HIV screening for all women attending cervical cancer screening clinics: This allows for risk stratification and tailored screening recommendations.
  • Regular cervical cancer screening for all women living with HIV: Annual screening is often recommended, but individual plans should be determined by a healthcare provider.
  • HPV vaccination for eligible women: Vaccination can prevent new HPV infections and reduce the risk of cervical cancer.
  • Improved access to healthcare services: Expanding access to screening and treatment, particularly in underserved areas, is crucial.
  • Increased awareness and education: Raising awareness about cervical cancer, HPV, and the importance of screening can empower women to take control of their health.

Further research is needed to evaluate the effectiveness of different screening strategies and interventions in women living with HIV in Suriname and other resource-limited settings. Continued surveillance of cervical cancer incidence and mortality rates is also essential to monitor progress and identify emerging trends. A collaborative effort involving healthcare providers, public health officials, and community organizations is needed to reduce the burden of cervical cancer and improve the health and well-being of women living with HIV.